| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Journal of Immunology, Vol 154, Issue 5 2303-2320, Copyright © 1995 by American Association of Immunologists
ARTICLES |
RJ Diefenbach and DE Isenman
Department of Biochemistry, University of Toronto, Ontario, Canada.
Most evidence points toward there being a shared binding site in complement receptor type 2 (CR2, CD21) for the complement ligand C3dg and the EBV surface envelope glycoprotein gp350/220. Indeed, synthetic peptide studies have suggested that the CR2-binding sites in human C3dg and EBV gp350/220 share a similar sequence motif. The proposed CR2- binding sequence in C3dg is EDPGKQLYNVEA (residues 1199-1210 of mature C3), whereas that in EBV gp350/220 is EDPGFFNVEI (residues identical to C3dg are underlined). To further examine the role of amino acids 1199- 1210 in the binding of the C3 fragments iC3b and C3dg to CR2, the following alanine-substitution variants of human C3 were tested in two independent CR2-binding assays: ED1199,1200AA; KQ1203,1204AA; L1205A; Y1206A; NV1207,1208AA; E1209A; and ED-KQ-NV1199,1200-1203,1204- 1207,1208AA-AA-AA. Also engineered and tested was a chimeric C3 molecule in which the 1199-1210 sequence (PVPGGYQLTLEA) from the non- CR2-binding trout C3 molecule was grafted onto a human C3 background. Recombinant C3 proteins were expressed transiently in COS-1 cells, deposited as C3b on C3 convertase-bearing sheep erythrocytes and finally converted to cell-bound iC3b or C3dg using factors H and I. Binding of EAC423bi and EAC423dg to CR2 on Raji cells or EAC423dg to soluble CR2 was assessed. In most cases, the substitutions had little effect on CR2-binding activity and even in the case of the most highly substituted variants, the decrease in CR2-binding activity was less than twofold. Thus, contrary to the results anticipated from synthetic peptide studies, the single and multiple substitutions to the C3 sequence tested failed to corroborate a role for the 1199-1210 sequence in the C3dg-CR2 interaction.
This article has been cited by other articles:
|
|
 |
|
  D. Morikis and J. D. Lambris The Electrostatic Nature of C3d-Complement Receptor 2 Association J. Immunol., June 15, 2004; 172(12): 7537 - 7547. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Sarrias, S. Franchini, G. Canziani, E. Argyropoulos, W. T. Moore, A. Sahu, and J. D. Lambris Kinetic Analysis of the Interactions of Complement Receptor 2 (CR2, CD21) with Its Ligands C3d, iC3b, and the EBV Glycoprotein gp350/220 J. Immunol., August 1, 2001; 167(3): 1490 - 1499. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Clemenza and D. E. Isenman Structure-Guided Identification of C3d Residues Essential for Its Binding to Complement Receptor 2 (CD21) J. Immunol., October 1, 2000; 165(7): 3839 - 3848. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. S. Hlavacek, C. Wofsy, and A. S. Perelson Dissociation of HIV-1 from follicular dendritic cells during HAART: Mathematical analysis PNAS, December 21, 1999; 96(26): 14681 - 14686. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. E. Oran and D. E. Isenman Identification of Residues within the 727-767 Segment of Human Complement Component C3 Important for Its Interaction with Factor H and with Complement Receptor 1 (CR1, CD35) J. Biol. Chem., February 19, 1999; 274(8): 5120 - 5130. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. T. Ogata, R. Ai, and P. J. Low Active Sites in Complement Component C3 Mapped by Mutations at Indels J. Immunol., November 1, 1998; 161(9): 4785 - 4794. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Nagar, R. G. Jones, R. J. Diefenbach, D. E. Isenman, and J. M. Rini X-ray Crystal Structure of C3d: A C3 Fragment and Ligand for Complement Receptor 2 Science, May 22, 1998; 280(5367): 1277 - 1281. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
